RGEN

In the past six months, Repligen's stock (RGEN) has shown significant upward momentum, with a 6-month return of 60.51% and a year-to-date gain of nearly 14%, reaching a new 52-week high of $188.95 on September 23, 2026. Key events include strong Q2 2026 results that exceeded Wall Street expectations, with adjusted earnings of $0.54 per share and revenue of $204 million, marking the company's 12th consecutive quarter meeting or beating expectations. Following this performance, Repligen raised its full-year 2026 guidance, projecting revenue between $813M-$834M and adjusted EPS of $2.03-$2.09. The acquisition of BioLife Solutions, expected to close in Q4 2026 after clearing an antitrust hurdle, is set to expand Repligen's cell therapy strategy. Analyst sentiment is largely positive, with a consensus 'Buy' rating and an average price target of $168.57, though some analysts see significant upside potential. However, insider selling totaling $10.8 million over the past 12 months, with no purchases, has been noted. Additionally, in Q1 2026, Repligen launched a Transformation Office to implement an efficiency plan focused on site rationalization, product-line optimization, and AI investment.